Upadacitinib

Indication

NICE TA665 - Upadacitinib for treating severe rheumatoid arthritis

MHRA Drug Safety Update, 26 April 2023

JAK Inhibitors MHRA Drug Safety Update

Red

Brand:

Nice TA:

665

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:

Musculoskeletal system

Background

1.1 Upadacitinib, with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs), only if:
• disease is severe (a disease activity score [DAS28] of more than 5.1) and
• the company provides upadacitinib according to the commercial arrangement.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Red	Red	Red	Red	Red	Red	Red	Red

What do the colours mean?

Last Updated: 14 - Jan - 2021